Teosyal RHA® Histology and Intradermal Implantation Evaluation Study

Histology Clinical Trial

Official title:
A Prospective, Single Blind, Single-center Study Evaluating the Histology and Intradermal Implantation of the Teosyal RHA® Collection of Fillers

Status Active, not recruiting

Clinical Trial Summary

The Teosyal RHA® family of products (RHA® 1, RHA® 2, RHA® 3, and RHA® 4) is approved in Canada for the correction of facial wrinkles and folds. In this study, the approved products will be placed in small boluses (0.2 mL) intradermally to allow for punch biopsies of the post-auricular space to be taken. The biopsies will include the injected material and surrounding skin tissue. Biopsies will be taken immediately after implantation of the product and at Day 30 and assessed by an independent blinded pathologist.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Histology

Clinical Trial Details

NCT number	NCT04846530
Study type	Observational
Source	Revance Therapeutics, Inc.
Contact
Status	Active, not recruiting
Phase
Start date	August 20, 2021
Completion date	December 13, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04650711` - Immunohistochemical Staining of p16 for the Screening of Cervical Cancer	Phase 2
Completed	`NCT05843526` - Influence of Implant Component Materials on Peri-implant Soft Tissue Horst Response.	N/A
Completed	`NCT01880021` - Synthetic Mesh Explant Study	N/A
Completed	`NCT01642693` - Histological Change of The Dentinal-Pulp Complex and Root Resorption	Phase 1/Phase 2
Completed	`NCT04577495` - Prognostic Factors in Patients Submitted to Surgical Treatment for Thymoma
Completed	`NCT03775811` - In Vivo Computer-aided Prediction of Polyp Histology on White Light Colonoscopy